Press release

Circio invites to a live webcast on 28 May 2026 to summarize the presentations at ASGCT 2026 and provide an overview of the warrants program

Circio presented an extensive circVec data package in an oral and a poster presentation at the ASGCT 2026 Annual Meeting
The warrant program exercise period between 26 May – 9 June offers the opportunity for warrant holders to subscribe for Circio shares at a discount to the VWAP from the warrant pricing period
CEO Dr. Erik D Wiklund will summarize the ASGCT presentation, provide an overview of the warrant process and planned use of proceeds for the warrant funds received

Oslo, Norway, 22 May 2026 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, invites to a live webcast in Norwegian at 10:00am CET on Thursday 28 May 2026.

In the webcast, CEO Dr. Erik D Wiklund will summarize the recent oral and poster presentations given at the ASGCT Annual Meeting in Boston 11-15 May 2026 where Circio presented an extensive data package showcasing the latest data package on its circVec circular RNA technology platform. The webcast will also include practical information and timelines relating to the warrant program with exercise period from 26 May to 9 June, including the planned use of proceeds for warrant funds received.

The webcast will be held in Norwegian. Questions can be submitted in advance by email to Erik D Wiklund: erik.wiklund@circio.com or directly in the live webcast.

Time: 10:00 CET on Thursday 28 May 2026

Click here to access Teams webcast
Meeting ID: 332 542 909 160 846
Passcode: kH6xK9CP

A recording of the webcast will be made available on the Circio webpage

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 50-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.